Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLII.h

Major/massive hemoptysis

Publications

Goto K, Endo M, Kusumoto M, Yamamoto N, Ohe Y, Shimizu A, Fukuoka M

Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis.

Cancer science 2016 Dec;107;1837-1842 — 2016 Dec — 1837-1842

Okamoto K, Okamoto I, Miyazaki M, Tanaka K, Kaneda H, Nakagawa K

Bronchoscopic findings for bevacizumab-related pulmonary hemorrhage in advanced non-small cell lung cancer.

Investigational new drugs 2013 Oct;31;1364-6 — 2013 Oct — 1364-6

Hapani S, Sher A, Chu D, Wu S

Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis.

Oncology 2010;79;27-38 — 2010 — 27-38

Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Oct 20;25;4743-50 — 2007 Oct 20 — 4743-50

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

The New England journal of medicine 2006 Dec 14;355;2542-50 — 2006 Dec 14 — 2542-50

Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Jun 01;22;2184-91 — 2004 Jun 01 — 2184-91